Investigation of Clinical Effects of Semaglutide Injection in Outpatients with Type 2 Diabetes

Real-World Clinical Effects of Semaglutide Injection in Outpatients with Type 2 Diabetes - Clinical Effects of Semaglutide Injection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000047011

Enrollment

Registered

2022-03-01

Start date

2021-10-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

The study term is six months. Participants are outpatients with type 2 diabetes in our hospital. They are categorized as cases of adding semaglutide injection to GLP-1RA-naive or switching from lirag

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type2 diabetes

Exclusion criteria

Exclusion criteria: 1.Patients with pregnancy 2.Patients with allergy 3.Patients who hospitalize over one week 4.Patients with serious gastrointestinal illness 5.Patients with cancer 6.Patients with a history of diabetic ketoacidosis and hyperglycemic crises 7.Patients with severe infection 8.Patients with high dose corticosteroid

Design outcomes

Primary

Measure	Time frame
Change of HbA1c at baseline and one, three and six months after semaglutide injection.	—

Secondary

Measure	Time frame
Body weight, Bioelectrical impedance analysis (BIA), Questionnaire of gastrointestinal symptoms, Diabetes treatment satisfaction questionnaire(DTSQ) at baseline and one, three and six months after semaglutide injection. Index of glycemic variability from professional CGM at baseline and six months	—

Countries

Japan

Contacts

Public ContactAkihiro Matsubara

Ichinomiyanishi Hospital Research Planning Division

matsubara@anzu.or.jp0586480077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026